US NEWS FEEDS
A court victory and help from a big investor have put Navidea Biopharmaceuticals Inc.'s balance sheet back in compliance with the New York Stock Exchange's standards, the Dublin company said Friday.
Navidea is trying to free itself from a morass of legal and financial woes even as clinical trials chug along on precision-targeted diagnostic agents for rheumatoid arthritis, heart disease and a rare form of cancer.
The company has received three warnings since August 2018 that it was in danger of…
Columbus Business News - Local Columbus News | Business First of Columbus
READ MORE >
Central Ohio public company finally ends de-listing threat with legal victory, private stock sale